Compare EFOI & LNAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | EFOI | LNAI |
|---|---|---|
| Founded | 1985 | N/A |
| Country | United States | United States |
| Employees | N/A | 29 |
| Industry | Building Products | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.2M | 11.9M |
| IPO Year | 2004 | N/A |
| Metric | EFOI | LNAI |
|---|---|---|
| Price | $2.09 | $0.30 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 8.0K | ★ 21.8M |
| Earning Date | 05-12-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 43.75 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $3,560,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.43 | $0.15 |
| 52 Week High | $3.56 | $1.66 |
| Indicator | EFOI | LNAI |
|---|---|---|
| Relative Strength Index (RSI) | 54.35 | 43.25 |
| Support Level | $1.94 | $0.15 |
| Resistance Level | $2.17 | $0.54 |
| Average True Range (ATR) | 0.12 | 0.07 |
| MACD | 0.01 | -0.00 |
| Stochastic Oscillator | 60.41 | 15.37 |
Energy Focus Inc engages in the design, development, manufacturing, marketing, and sale of energy-efficient lighting systems and controls. The company serves the military maritime market and general commercial markets. Its product offerings include Military maritime LED lighting products such as military intelligible, globe lights, berth lights, and military fixtures and Commercial products such as LED fixtures and panels, LED down-lights, LED dock lights, and LED retrofit kits. Geographically, it operates in the United States and other countries. Its products include commercial products and MMM products. The company generates a majority of its sales from Military maritime products in the United States.
Lunai Bioworks Inc is a biopharmaceutical company. Through its subsidiaries, it is mainly focused on developing allogeneic cell and gene therapies to promote stronger immune system responses, potentially for long-term or life-long cancer remission in some of the deadliest cancers. The group is engaged in the development of RENB-DC11 and RENB-DC20 (potential cell therapeutic vaccine candidates for different types of cancer); a proprietary AI platform that analyzes genetics to provide earlier and more accurate cancer diagnosis; and machine learning pipelines that harmonize and analyze complex, heterogeneous datasets to uncover clinically actionable insights. The group's reportable segments are: RENB, BioSymetrics, and RENC. Geographically, it operates in the United States and Netherlands.